AVBP earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -8.62. Updated 2026-07-23.
ArriVent BioPharma (AVBP) Research Hub
ArriVent BioPharma (AVBP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 29 USD (-2.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.62, market cap 1.40B. This hub links to the full technical, earnings and options research available for AVBP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 29 USD (-2.65%) |
| 52-week range | 27.94 USD – 35.83 USD |
| Trend regime | Range |
| 14-day RSI | 41.8 (Bearish) |
| Trailing P/E | -8.62 |
| Market cap | 1.40B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AVBP
Covered Call on AVBP: how it works, illustrative setup around the real 29 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AVBP: how it works, illustrative setup around the real 29 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AVBP: how it works, illustrative setup around the real 29 USD price, max profit/loss, breakeven and when to use it. Educational.
AVBP technical analysis: range, last 29 USD, RSI 41.8, 52w range 27.94 USD–35.83 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AVBP in?
ArriVent BioPharma (AVBP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AVBP in an uptrend or downtrend?
As of 2026-09-11, AVBP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AVBP's trailing P/E ratio?
AVBP's trailing P/E is -8.62, with a market cap of 1.40B. See the earnings research page for full valuation detail.
When does AVBP next report earnings?
AVBP is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.98 USD.